www.fgks.org   »   [go: up one dir, main page]
Benchmarks
Nifty17,670.45205.7
Market Watch
The Economic Times
English Edition
| 02 April, 2022, 08:24 AM IST | E-Paper
ET Prime starts @ Rs 49ET Prime Summer SALEUpgrade at 50% discount
Search
+
Business News›Markets›Stocks›Stock Price Quotes›Cadila Healthcare Share Price

Zydus Lifesciences - Share Price, Stock Analysis & Recos

  • 354.405.90 (1.69%)
  • Volume: 10,81,594
  • Closed
  • Last Updated On: 01 Apr, 2022, 03:58 PM IST
STOCK SCORE
ETPrime Only

What’s Stock Score?

Stock Score is the Average Score from Stock Reports Plus by Refinitiv which combines quantitative analysis of widely used investment decision making tools. This score is on a 10 point scale (1 is lowest and 10 being the highest, NR indicates No-rating is available)

You can access 4000+ Stock Reports with ET Prime. Know More

VIEW STOCK REPORT
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • TECHNICALS
  • COMPARE
  • Overview
  • News
  • Analysis
  • Recos
  • Financials
  • Forecast
  • Technicals
  • Peers
  • Shareholdings
  • MF
  • F&O
  • Corp Actions
  • About
  • More
    • MF
    • F&O
    • Corp Actions
    • About
  • Rank 109 - ET 5002021 ranking

Insights

View All

  • In the last 17 years, only 2.17 % trading sessions saw intraday gains higher than 5 % .

  • Company has spent 1.08% of its operating revenues towards interest expenses and 16.49% towards employee cost in the year ending 31 Mar, 2021. (Source: Consolidated Financials)

  • White Spinning Top was formed for Cadila Healthcare

  • Stock gave a 3 year return of 3.01% as compared to Nifty 100 which gave a return of 49.25%. (as of last trading session)

InsightsZydus Lifesciences Ltd.

  • Intraday fact check

    In the last 17 years, only 2.17 % trading sessions saw intraday gains higher than 5 % .

  • Employee & Interest Expense

    Company has spent 1.08% of its operating revenues towards interest expenses and 16.49% towards employee cost in the year ending 31 Mar, 2021. (Source: Consolidated Financials)

  • Candle Formations Yesterday

    White Spinning Top was formed for Cadila Healthcare

  • Stock Returns vs Nifty 100

    Stock gave a 3 year return of 3.01% as compared to Nifty 100 which gave a return of 49.25%. (as of last trading session)

Do you find these insights useful?

  • hate it

  • meh

  • love it

Key Metrics

  • PE Ratio

    PE Ratio

    This is a ratio arrived at by dividing the current market price of a stock by its latest (annual or annualized) earnings per share. Here we have taken the TTM (trailing twelve months) adjusted earnings per share.

    (x)
    7.61
  • EPS - TTM

    EPS - TTM

    Earnings per share (TTM) tells the profit after tax earned on a per share basis by a stock over the last twelve months or four quarters.

    (₹)
    46.58
  • MCap

    MCap

    MCap or Market capitalization of a stock is calculated by multiplying the total number of shares outstanding of that particular stock with its current market price.

    (₹ Cr.)
    36,281.44
  • Sectoral MCap Rank

    Sectoral MCap Rank

    This is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned.

    11
  • PB Ratio

    PB Ratio

    Price to Book represents the ratio of current market price of a stock to its book value per share. The book value itself is arrived at by dividing the net worth of a company by the total number of shares outstanding of the company at that time.

    (x)
    2.39
  • Div Yield

    Dividend Yield

    Dividend Yield calculates the amount of full year dividend declared by a company as a percentage of the current market price of a stock. All other things being equal, higher the dividend yield of the stock, the better it is for investors.

    (%)
    0.99
  • Face Value

    Face Value

    Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value.

    (₹)
    1.00
  • Beta

    Beta

    1 Month1.50
    3 Months1.42
    6 Months1.14
    1 Year0.99
    3 Years1.11

    1.50
  • VWAP

    VWAP

    Volume Weighted Average Price represents the average price of a security over a particular time period (example one trading day) weighted by the volume traded at each price point.

    (₹)
    351.69
  • 52W H/L

    52W H/L

    This represents the 52 week high and low price of the security. It is also the 1 year high and low of the security. This represents the highest and lowest price touched by the security during the past 52 weeks or 1 year including today.

    (₹)
    673.70 / 331.55

Returns

  • 1 Day1.69%
  • 1 Week-1.32%
  • 1 Month-1.66%
  • 3 Months-26.65%
  • 1 Year-19.78%
  • 3 Years2.95%
  • 5 Years-19.82%

ET Stock ScreenersTop Score Companies

Check whether Cadila Healthcare belongs to analysts' top-rated companies list?

View Stock Screeners

Cadila Healthcare News & Analysis

View all News & Announcements

Cadila Healthcare Stock Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Stock Analysis Non Prime User
  • View Stock Score on a 10-point scale
  • See ratings on Earning, Fundamentals, Valuation, Risk & Price
  • Check stock performance
START FREE TRIAL

Recommendations

Recent Recos

BUY

Current

Mean Recos by 30 Analysts

Strong
SellSellHoldBuyStrong
Buy

That's all for Cadila Healthcare recommendations. Check out other stock recos.

Analyst Trends

RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
Strong Buy5555
Buy1313139
Hold8789
Sell2223
Strong Sell2224
# Analysts30293030
View all Recommendations

Financials

  • Income (P&L)

  • Balance Sheet

  • Cash Flow

  • Ratios

  • Insights

    • Employee & Interest Expense

      Company has spent 1.08% of its operating revenues towards interest expenses and 16.49% towards employee cost in the year ending 31 Mar, 2021. (Source: Consolidated Financials)
    Quarterly | AnnualDec 2021Sep 2021Jun 2021Mar 2021Dec 2020
    Total Income3,715.803,838.104,057.003,806.403,823.10
    Total Income Growth (%)-3.19-5.406.58-0.44-0.63
    Total Expenses3,085.703,204.503,275.103,253.103,169.10
    Total Expenses Growth (%)-3.71-2.160.682.65-3.01
    EBIT630.10633.60781.90553.30654.00
    EBIT Growth (%)-0.55-18.9741.32-15.4012.78
    Profit after Tax (PAT)500.403,002.30587.20679.00527.20
    PAT Growth (%)-83.33411.29-13.5228.7911.36
    EBIT Margin (%)16.9616.5119.2714.5417.11
    Net Profit Margin (%)13.4778.2214.4717.8413.79
    Basic EPS (₹)4.8929.325.746.635.15
    Quarterly | AnnualDec 2021Sep 2021Jun 2021Mar 2021Dec 2020
    Total Income1,856.202,078.302,153.101,991.901,943.80
    Total Income Growth (%)-10.69-3.478.092.47-8.21
    Total Expenses1,591.701,963.101,622.501,529.601,721.30
    Total Expenses Growth (%)-18.9220.996.07-11.1411.67
    EBIT264.50115.20530.60462.30222.50
    EBIT Growth (%)129.60-78.2914.77107.78-61.39
    Profit after Tax (PAT)197.0014.10399.90464.70140.30
    PAT Growth (%)1,297.16-96.47-13.94231.22-70.34
    EBIT Margin (%)14.255.5424.6423.2111.45
    Net Profit Margin (%)10.610.6818.5723.337.22
    Basic EPS (₹)1.920.143.914.541.37
    Quarterly | Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Total Revenue15,139.4014,367.0013,366.7012,018.109,504.90
    Total Revenue Growth (%)5.387.4811.2226.44-0.39
    Total Expenses12,649.5012,508.0010,974.209,687.307,890.00
    Total Expenses Growth (%)1.1313.9813.2822.786.03
    Profit after Tax (PAT)2,133.601,176.601,848.801,775.801,487.70
    PAT Growth (%)81.34-36.364.1119.37-23.07
    Operating Profit Margin (%)17.5615.4419.6420.3417.69
    Net Profit Margin (%)14.128.2514.0414.9115.86
    Basic EPS (₹)20.8411.4918.0617.3514.53
    Quarterly | Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Total Revenue7,869.307,196.806,596.706,017.803,813.80
    Total Revenue Growth (%)9.349.109.6257.79-47.08
    Total Expenses5,993.305,587.104,855.404,520.603,171.60
    Total Expenses Growth (%)7.2715.077.4142.53-32.56
    Profit after Tax (PAT)1,476.201,412.901,485.701,090.80661.90
    PAT Growth (%)4.48-4.9036.2064.80-67.51
    Operating Profit Margin (%)24.9929.0430.3226.8620.22
    Net Profit Margin (%)18.9422.2524.6018.7720.48
    Basic EPS (₹)14.4213.8014.5110.666.47

    All figures in Rs Cr, unless mentioned otherwise

    View Details
  • Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Total Assets23,884.7023,686.6023,483.1018,065.3015,220.70
    Total Assets Growth (%)0.840.8729.9918.6944.26
    Total Liabilities8,955.1011,976.2011,803.909,129.808,104.60
    Total Liabilities Growth (%)-25.231.4629.2912.6571.87
    Total Equity14,929.6011,710.4011,679.208,935.507,116.10
    Total Equity Growth (%)27.490.2730.7125.5721.96
    Current Ratio (x)1.111.051.161.351.14
    Total Debt to Equity (x)0.280.680.690.580.71
    Contingent Liabilities1,295.501,053.70930.00667.40629.30
    Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Total Assets18,463.6016,551.5013,671.1012,163.7011,047.40
    Total Assets Growth (%)11.5521.0712.3910.1023.81
    Total Liabilities5,719.105,291.305,101.904,418.204,429.10
    Total Liabilities Growth (%)8.083.7115.47-0.2567.33
    Total Equity12,744.5011,260.208,569.207,745.506,618.30
    Total Equity Growth (%)13.1831.4010.6317.035.45
    Current Ratio (x)1.251.391.521.270.71
    Total Debt to Equity (x)0.260.260.390.340.42
    Contingent Liabilities2,009.304,090.903,592.602,855.102,594.20

    All figures in Rs Cr, unless mentioned otherwise

    View Details

  • Insights

    • Decrease in Cash from Investing

      Company has used Rs 722.5 cr for investing activities which is an YoY decrease of 28.63%. (Source: Consolidated Financials)
    Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Net Cash flow from Operating Activities3,293.002,931.501,281.90919.301,311.70
    Net Cash used in Investing Activities-722.50-1,012.30-4,238.70-973.70-2,871.90
    Net Cash flow from Financing Activities-2,548.90-1,528.201,884.6051.502,315.80
    Net Cash Flow-90.50398.90-810.90-2.90755.60
    Closing Cash & Cash Equivalent1,087.201,177.70778.801,589.701,592.60
    Closing Cash & Cash Equivalent Growth (%)-7.6851.22-51.01-0.1890.27
    Total Debt/ CFO (x)1.122.405.585.563.77
    Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Net Cash flow from Operating Activities2,225.301,180.60580.70289.20867.10
    Net Cash used in Investing Activities-2,713.8055.00-745.2026.50-2,479.70
    Net Cash flow from Financing Activities257.20-966.7064.90-148.701,365.60
    Net Cash Flow-231.30268.50-67.00167.00-247.00
    Closing Cash & Cash Equivalent154.00385.30116.80183.8016.80
    Closing Cash & Cash Equivalent Growth (%)-60.03229.88-36.45994.05-93.63
    Total Debt/ CFO (x)1.492.505.769.173.21

    All figures in Rs Cr, unless mentioned otherwise

    View Details
  • Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Return on Equity (%)16.4211.3317.8020.3021.37
    Return on Capital Employed (%)16.5514.2716.0220.2116.73
    Return on Assets (%)8.934.967.879.829.77
    Interest Coverage Ratio (x)16.236.4413.3626.5937.21
    Asset Turnover Ratio (x)63.2260.1756.0665.8961.60
    Price to Earnings (x)21.1923.2619.2321.8830.58
    Price to Book (x)3.472.643.424.436.52
    EV/EBITDA (x)14.7612.0013.6214.4424.08
    EBITDA Margin (%)22.3620.3224.1824.8621.67
    Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
    Return on Equity (%)11.5812.5417.3314.0810.00
    Return on Capital Employed (%)14.2714.0716.8516.658.13
    Return on Assets (%)7.998.5310.868.965.99
    Interest Coverage Ratio (x)27.467.8820.4324.4358.86
    Asset Turnover Ratio (x)42.1938.3444.1647.7629.24
    Price to Earnings (x)30.5819.3823.9235.5968.97
    Price to Book (x)3.542.434.145.016.86
    EV/EBITDA (x)20.1413.1717.6922.2453.26
    EBITDA Margin (%)30.7835.8036.2531.9127.98

Financial InsightsZydus Lifesciences Ltd.

  • Income (P&L)
  • Cash Flow

    • Employee & Interest Expense

      Company has spent 1.08% of its operating revenues towards interest expenses and 16.49% towards employee cost in the year ending 31 Mar, 2021. (Source: Consolidated Financials)

    • Decrease in Cash from Investing

      Company has used Rs 722.5 cr for investing activities which is an YoY decrease of 28.63%. (Source: Consolidated Financials)

Do you find these insights useful?

  • hate it

  • meh

  • love it

Forecast

  • PRICE

  • REVENUE

  • EARNINGS

  • Get multiple analysts’ prediction on Cadila Healthcare

    Stock Forecast Non Prime User
    • High, low, medium predictions for Price
    • Upcoming predictions for Revenue
    • Details about company earnings
    START FREE TRIAL

  • Get multiple analysts’ prediction on Cadila Healthcare

    Stock Forecast Non Prime User
    • High, low, medium predictions for Price
    • Upcoming predictions for Revenue
    • Details about company earnings
    START FREE TRIAL

  • Get multiple analysts’ prediction on Cadila Healthcare

    Stock Forecast Non Prime User
    • High, low, medium predictions for Price
    • Upcoming predictions for Revenue
    • Details about company earnings
    START FREE TRIAL

Technicals

  • Buy / Sell Signals

  • Price Analysis

  • Pivot Levels & ATR

  • Chart

  • Bullish / Bearish signals for Zydus Lifesciences Ltd. basis selected technical indicators and moving average crossovers.

    Stochastic Crossover

    Bearish signal on weekly chart

    Appeared on: 1 Apr 2022

    Region: Oversold (Below 20)

    Last 4 Sell Signals:18 Feb 2022
    Date7 weeks Gain/Loss %
    18 Feb 2022-11.95%
    14 Jan 2022-13.99%
    17 Dec 2021-5.05%
    8 Oct 2021-11.60%

    Average price decline of -6.60% within 7 weeks of Bearish signal in last 10 years

  • 44%
    Positive Movement since
    1st Jan 2005 on basis
    56%
    Negative Movement since
    1st Jan 2005 on basis
    Exclude

  • Pivot Levels

    R1R2R3PIVOTS1S2S3
    Classic357.68360.97370.07351.87348.58342.77333.67

    Average True Range

    5 DAYS14 DAYS28 DAYS
    ATR9.4310.4111.06

Peer Comparison

  • Stock Performance

  • Ratio Performance

    • CHART
    • TABLE

    Insights

    • Stock Returns vs Nifty 100

      Stock gave a 3 year return of 3.01% as compared to Nifty 100 which gave a return of 49.25%. (as of last trading session)

    • Stock Returns vs Nifty Pharma

      Stock generated 3.01% return as compared to Nifty Pharma which gave investors 44.89% return over 3 year time period. (as of last trading session)

    • Choose from Peers

        Choose from Stocks

        • 1D
        • 1W
        • 1M
        • 3M
        • 6M
        • 1Y
        • 5Y

      • Insights

        • Stock Returns vs Nifty 100

          Stock gave a 3 year return of 3.01% as compared to Nifty 100 which gave a return of 49.25%. (as of last trading session)

        • Stock Returns vs Nifty Pharma

          Stock generated 3.01% return as compared to Nifty Pharma which gave investors 44.89% return over 3 year time period. (as of last trading session)

        Ratio Performance

        NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
        Cadila Healthcare7.612.4316.4216.558.937.9217.5614.1520.841.110.281.12
        Gland Pharma46.309.3016.8822.3615.3428.8538.6428.7963.0710.000.000.01
        Torrent Pharma38.698.0821.4420.528.898.5823.5415.6373.981.130.621.81
        Alkem Labs23.495.5321.4824.0113.7511.6421.4418.24132.571.920.231.32
        Biocon61.914.839.838.323.9919.1416.7712.886.241.810.473.07
        Add More
        Annual Ratios (%)

        Choose from Peers

        • Aurobindo Pharma
        • Lupin
        • Aarti Inds
        • Laurus Labs
        • Syngene Int.

        Choose from Stocks

          See All Parameters

        Peers InsightsZydus Lifesciences Ltd.

        • Stock Returns vs Nifty 100

          Stock gave a 3 year return of 3.01% as compared to Nifty 100 which gave a return of 49.25%. (as of last trading session)

        • Stock Returns vs Nifty Pharma

          Stock generated 3.01% return as compared to Nifty Pharma which gave investors 44.89% return over 3 year time period. (as of last trading session)

        Do you find these insights useful?

        • hate it

        • meh

        • love it

        Shareholding Pattern

        • QOQ Change

        • Total Shareholdings

        • Showing Shareholding as on 31 Dec 2021
          Category31 Dec 202130 Sep 202130 Jun 202131 Mar 2021
          Promoters74.8874.8874.8874.88
          Pledge0.000.000.000.00
          FII3.794.114.655.23
          DII11.8111.2510.4911.30
          Mutual Funds4.854.795.836.41
          Others9.529.769.988.59
        • Showing Shareholding as on 31 Dec 2021
          CategoryNo. of SharesPercentage% Change QoQ
          Promoters76,65,34,43474.88 %0.00
          Pledge00.00 %0.00
          FII3,88,06,8943.79 %-0.32
          DII12,08,32,35511.81 %0.56
          MF4,96,39,9434.85 %0.06
          Others9,75,68,9179.52 %-0.24

        MF Ownership

        MF Ownership as on 28 February 2022

        View all Schemes

        Top Searches:

        Cadila Healthcare News Cadila Healthcare Quarterly Results Cadila Healthcare Dividend Cadila Healthcare Q1 ResultsCadila Healthcare Q2 ResultsCadila Healthcare Q3 ResultsCadila Healthcare Q4 Results

        F&O Quote

        • Futures

        • Options

          • Expiry

          Price

          355.855.35 (1.53%)

          Open Interest

          1,82,87,500-8,800 (-0.05%)

          OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
          351.00356.60348.00350.502,5389,861.78

          Open Interest as of 01 Apr 2022

        Corporate Actions

        • Board Meeting/AGM

        • Dividends

        • Others
        • Meeting DateAnnounced onPurposeDetails
          Feb 18, 2022Jan 25, 2022EGM-
          Feb 03, 2022Jan 25, 2022Board MeetingQuarterly Results
          Oct 29, 2021Oct 20, 2021Board MeetingQuarterly Results
          Aug 11, 2021Aug 03, 2021Board MeetingQuarterly Results
          Aug 11, 2021May 27, 2021AGMBook closure from 30 Jul, 2021 to 6 Aug, 2021
        • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
          Final350%3.5Jul 28, 2021May 27, 2021
          Interim350%3.5Mar 23, 2020Mar 11, 2020
          Final350%3.5Jul 25, 2019May 29, 2019
          Final350%3.5Jul 31, 2018May 25, 2018
          Interim320%3.2Mar 16, 2017Feb 20, 2017
        • All TypesEx-DateRecord DateAnnounced onDetails
          SplitsOct 06, 2015Oct 07, 2015Aug 12, 2015Split: Old FV5.0| New FV:1.0
          BonusApr 05, 2010Apr 06, 2010Feb 25, 2010Bonus Ratio: 1 share(s) for every 2 shares held
          BonusAug 30, 2006Aug 31, 2006Apr 28, 2006Bonus Ratio: 1 share(s) for every 1 shares held

        About Cadila Healthcare

        Zydus Lifesciences Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 36,281.44 Crore) operating in Pharmaceuticals sector. Zydus Lifesciences Ltd. key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2021. Show More

        • Executives

        • Auditors

        • PR

          Pankaj R Patel

          Chairman
          SP

          Sharvil P Patel

          Managing Director
          GN

          Ganesh N Nayak

          Executive Director
          MM

          Mukesh M Patel

          Non Executive Director
          Show More
        • Deloitte Haskins & Sells LLP

        Industry

        Pharma - Indian

        Key Indices Listed on

        Nifty Next 50, Nifty 100, Nifty 200, + 20 more

        Address

        Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar),Nr. Vaishnodevi Circle,Ahmedabad, Gujarat - 382481

        Contact

        investor.grievance@zyduscadila.com

        http://www.zyduscadila.com

        More Details

        FAQs about Cadila Healthcare

        • 1. What is Cadila Healthcare share price and what are the returns for Cadila Healthcare share?
          Cadila Healthcare share price was Rs 354.40 as on 01 Apr, 2022, 03:58 PM IST. Cadila Healthcare share price was up by 1.69% based on previous share price of Rs. 355.85. In last 1 Month, Cadila Healthcare share price moved down by 1.66%.
        • 2. What is 52 week high/low of Cadila Healthcare share price?
          In last 52 weeks Cadila Healthcare share had a high price of Rs 673.70 and low price of Rs 331.55
        • 3. What is the market cap of Cadila Healthcare?
          Cadila Healthcare share has a market capitalization of Rs 36,281.44 Cr. Within Pharmaceuticals sector, it's market cap rank is 11.
        • 4. Who owns Cadila Healthcare?
          Following are the key changes to Cadila Healthcare shareholding:
          • Promoter holding has not changed in last 9 months and holds 74.88 stake as on 31 Dec 2021
          • Domestic Institutional Investors holding has gone up from 11.3 (31 Mar 2021) to 11.81 (31 Dec 2021)
          • Foreign Institutional Investors holding have gone down from 5.23 (31 Mar 2021) to 3.79 (31 Dec 2021)
          • Other investor holding has gone up from 8.59 (31 Mar 2021) to 9.52 (31 Dec 2021)
        • 5. Which are the key peers to Cadila Healthcare?
          Top 10 Peers for Cadila Healthcare are Aarti Industries Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Laurus Labs Ltd., Biocon Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Torrent Pharmaceuticals Ltd., Syngene International Ltd. and Gland Pharma Ltd.
        • 6. How can I quickly analyze Cadila Healthcare stock?
          Cadila Healthcare share can be quickly analyzed on following metrics:
          • Stock's PE is 7.61
          • Price to Book Ratio of 2.39
          • Dividend Yield of 0.99
          • EPS (trailing 12 month) of Cadila Healthcare share is 46.58

        Cadila Healthcare Share Price Update

        Zydus Lifesciences Ltd. share price moved up by 1.69% from its previous close of Rs 348.50. Zydus Lifesciences Ltd. stock last traded price is 354.40

        Share PriceValue
        Today/Current/Last354.40
        Previous Day348.50

        Trending in Markets

        DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

        DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

        By using this site, you agree to the Terms of Service and Privacy Policy.

        The Economic Times